Among 200 dialysis patients, 37% were non-compliant with their phosphate binders compared with 12% to 18% of patients who ...

BOSTON — Patients on kidney dialysis reported better adherence ... and 126 answered questions about barriers to phosphate binder adherence. Forgetting to take the medication was listed as ...

Explore medication options for kidney disease and potential side effects. Learn the best treatment options to slow ...

The worldwide hyperphosphatemia industry is anticipated to reach a valuation of around USD 12.66 billion in 2023 and grow at a compound annual growth rate (CAGR) of more than 4.8% until 2033. By 2033, ...

(Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today ...

on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. XPHOZAH offers a different mechanism ...

Background: Aluminium-containing phosphate binders have long been used for treatment of hyperphosphatemia in dialysis patients. Their safety became controversial in the early 1980's after reports ...

on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. XPHOZAH offers a different mechanism of ...